ScreenerHero
HLNHaleon plc American Depositary Shares (Each representing two Ordinary Shares)
NYSE · US · Consumer Defensive · Drug Manufacturers - Specialty & Generic · haleon.com
9.995USD+1.27%Mkt Cap: 43.41B $P/E: 20.14

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the As…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.24BUSDP/E 23.7
ZOE
Zoetis Inc.
$29.37BUSDP/E 12.4
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.5
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
HIK
Hikma Pharmaceuticals PLC
$4.32BUSDP/E 12.5
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
SFZN
Siegfried Holding AG
$3.91BUSDP/E 20.4
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.32BUSDP/E 16.5
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD
ALM
Almirall, S.A.
$2.47BUSDP/E 37.4

Key Statistics

Company
Market Cap43.41B $
Enterprise Value51.33B $
Revenue (TTM)11.15B $
Gross Profit7.08B $
Net Income (TTM)1.67B $
Revenue/Share2.504 USD
Last Price9.995 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees24.5K
CountryUS
SectorConsumer Defensive
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)20.14
P/E (Forward)15.84
PEG2.43
EV/EBITDA18.02
EV/Revenue4.60
P/S3.89
P/B1.98
EPS (TTM)0.49
EPS (Forward)0.62
52W Range
9.565100% of range9.960
52W High9.960 USD
52W Low9.565 USD
Profitability
Gross Margin64.19%
Oper. Margin23.94%
EBITDA Margin25.54%
Profit Margin15.11%
ROE10.15%
ROA5.11%
Growth
Revenue Growth2.20%
Earnings Growth-4.50%
Cash Flow & Leverage
Operating CF2.63B $
CapEx (TTM)413.00M $
FCF Margin16.16%
FCF Yield4.15%
Net Debt7.43B $
Net Debt/EBITDA2.61
Balance Sheet
Debt/Equity0.52
Current Ratio0.69
Quick Ratio0.51
Book Value/Sh4.992 USD
Cash/Share0.1860 USD
Dividends
Fwd Div Rate0.2000 USD
Trail. Div Rate0.0730 USD
Div. Yield2.00%
5Y Avg Yield—
Payout Ratio39.53%
Ex-Div DateAug 14, 2026
Pay DateSep 17, 2026
Analyst Consensus
Rating—
Target (Mean)11.99 USD
Upside (mean)+20.0%
Target Range10.00 USD – 13.77 USD
$10.00+20.0% to mean$13.77
# Analysts5
Ownership
Shares Out.4.40B
Float4.43B
Insiders0.01%
Institutions13.54%
Short Interest
Short Ratio1.7d
Short % Float0.41%
Short % Out.0.41%
Shares Short18.10M
Short (prev mo.)14.11M
Technical
SMA 509.649 (+3.6%)
SMA 2009.821 (+1.8%)
Beta0.24
S&P 52W Chg18.16%
Avg Vol (30d)8.15M
Avg Vol (10d)6.46M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—